Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany
Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Schöffski, Oliver [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1996 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: PharmacoEconomics - Berlin [u.a.] : Springer, 1992, 10(1996), Suppl 2 vom: Dez., Seite 37-47 |
|---|---|
| Übergeordnetes Werk: |
volume:10 ; year:1996 ; number:Suppl 2 ; month:12 ; pages:37-47 |
| Links: |
|---|
| DOI / URN: |
10.2165/00019053-199600102-00007 |
|---|
| Katalog-ID: |
SPR033323690 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR033323690 | ||
| 003 | DE-627 | ||
| 005 | 20230519232554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s1996 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2165/00019053-199600102-00007 |2 doi | |
| 035 | |a (DE-627)SPR033323690 | ||
| 035 | |a (SPR)00019053-199600102-00007-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Schöffski, Oliver |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| 264 | 1 | |c 1996 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. | ||
| 650 | 4 | |a Adis International Limited |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Reference Price |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Sickness Fund |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a German Physician |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Parallel Import |7 (dpeaa)DE-He213 | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d Berlin [u.a.] : Springer, 1992 |g 10(1996), Suppl 2 vom: Dez., Seite 37-47 |w (DE-627)327645717 |w (DE-600)2043876-X |x 1179-2027 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:1996 |g number:Suppl 2 |g month:12 |g pages:37-47 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2165/00019053-199600102-00007 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2190 | ||
| 936 | b | k | |a 44.40 |q ASE |
| 951 | |a AR | ||
| 952 | |d 10 |j 1996 |e Suppl 2 |c 12 |h 37-47 | ||
| author_variant |
o s os |
|---|---|
| matchkey_str |
article:11792027:1996----::osqecsfmlmnigdubdefrfieae |
| hierarchy_sort_str |
1996 |
| bklnumber |
44.40 |
| publishDate |
1996 |
| allfields |
10.2165/00019053-199600102-00007 doi (DE-627)SPR033323690 (SPR)00019053-199600102-00007-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Schöffski, Oliver verfasserin aut Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 10(1996), Suppl 2 vom: Dez., Seite 37-47 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 https://dx.doi.org/10.2165/00019053-199600102-00007 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 10 1996 Suppl 2 12 37-47 |
| spelling |
10.2165/00019053-199600102-00007 doi (DE-627)SPR033323690 (SPR)00019053-199600102-00007-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Schöffski, Oliver verfasserin aut Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 10(1996), Suppl 2 vom: Dez., Seite 37-47 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 https://dx.doi.org/10.2165/00019053-199600102-00007 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 10 1996 Suppl 2 12 37-47 |
| allfields_unstemmed |
10.2165/00019053-199600102-00007 doi (DE-627)SPR033323690 (SPR)00019053-199600102-00007-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Schöffski, Oliver verfasserin aut Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 10(1996), Suppl 2 vom: Dez., Seite 37-47 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 https://dx.doi.org/10.2165/00019053-199600102-00007 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 10 1996 Suppl 2 12 37-47 |
| allfieldsGer |
10.2165/00019053-199600102-00007 doi (DE-627)SPR033323690 (SPR)00019053-199600102-00007-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Schöffski, Oliver verfasserin aut Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 10(1996), Suppl 2 vom: Dez., Seite 37-47 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 https://dx.doi.org/10.2165/00019053-199600102-00007 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 10 1996 Suppl 2 12 37-47 |
| allfieldsSound |
10.2165/00019053-199600102-00007 doi (DE-627)SPR033323690 (SPR)00019053-199600102-00007-e DE-627 ger DE-627 rakwb eng 610 ASE 44.40 bkl Schöffski, Oliver verfasserin aut Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany 1996 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 Enthalten in PharmacoEconomics Berlin [u.a.] : Springer, 1992 10(1996), Suppl 2 vom: Dez., Seite 37-47 (DE-627)327645717 (DE-600)2043876-X 1179-2027 nnns volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 https://dx.doi.org/10.2165/00019053-199600102-00007 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 44.40 ASE AR 10 1996 Suppl 2 12 37-47 |
| language |
English |
| source |
Enthalten in PharmacoEconomics 10(1996), Suppl 2 vom: Dez., Seite 37-47 volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 |
| sourceStr |
Enthalten in PharmacoEconomics 10(1996), Suppl 2 vom: Dez., Seite 37-47 volume:10 year:1996 number:Suppl 2 month:12 pages:37-47 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Adis International Limited Reference Price Sickness Fund German Physician Parallel Import |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
PharmacoEconomics |
| authorswithroles_txt_mv |
Schöffski, Oliver @@aut@@ |
| publishDateDaySort_date |
1996-12-01T00:00:00Z |
| hierarchy_top_id |
327645717 |
| dewey-sort |
3610 |
| id |
SPR033323690 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033323690</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232554.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1996 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199600102-00007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033323690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199600102-00007-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schöffski, Oliver</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reference Price</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sickness Fund</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">German Physician</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parallel Import</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">10(1996), Suppl 2 vom: Dez., Seite 37-47</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:37-47</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199600102-00007</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">1996</subfield><subfield code="e">Suppl 2</subfield><subfield code="c">12</subfield><subfield code="h">37-47</subfield></datafield></record></collection>
|
| author |
Schöffski, Oliver |
| spellingShingle |
Schöffski, Oliver ddc 610 bkl 44.40 misc Adis International Limited misc Reference Price misc Sickness Fund misc German Physician misc Parallel Import Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| authorStr |
Schöffski, Oliver |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)327645717 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1179-2027 |
| topic_title |
610 ASE 44.40 bkl Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany Adis International Limited (dpeaa)DE-He213 Reference Price (dpeaa)DE-He213 Sickness Fund (dpeaa)DE-He213 German Physician (dpeaa)DE-He213 Parallel Import (dpeaa)DE-He213 |
| topic |
ddc 610 bkl 44.40 misc Adis International Limited misc Reference Price misc Sickness Fund misc German Physician misc Parallel Import |
| topic_unstemmed |
ddc 610 bkl 44.40 misc Adis International Limited misc Reference Price misc Sickness Fund misc German Physician misc Parallel Import |
| topic_browse |
ddc 610 bkl 44.40 misc Adis International Limited misc Reference Price misc Sickness Fund misc German Physician misc Parallel Import |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
PharmacoEconomics |
| hierarchy_parent_id |
327645717 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
PharmacoEconomics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)327645717 (DE-600)2043876-X |
| title |
Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| ctrlnum |
(DE-627)SPR033323690 (SPR)00019053-199600102-00007-e |
| title_full |
Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| author_sort |
Schöffski, Oliver |
| journal |
PharmacoEconomics |
| journalStr |
PharmacoEconomics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
1996 |
| contenttype_str_mv |
txt |
| container_start_page |
37 |
| author_browse |
Schöffski, Oliver |
| container_volume |
10 |
| class |
610 ASE 44.40 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Schöffski, Oliver |
| doi_str_mv |
10.2165/00019053-199600102-00007 |
| dewey-full |
610 |
| title_sort |
consequences of implementing a drug budget for office-based physicians in germany |
| title_auth |
Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| abstract |
Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. |
| abstractGer |
Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. |
| abstract_unstemmed |
Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA SSG-OPC-PHA SSG-OPC-ASE GBV_ILN_702 GBV_ILN_2190 |
| container_issue |
Suppl 2 |
| title_short |
Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany |
| url |
https://dx.doi.org/10.2165/00019053-199600102-00007 |
| remote_bool |
true |
| ppnlink |
327645717 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.2165/00019053-199600102-00007 |
| up_date |
2024-07-03T17:56:46.655Z |
| _version_ |
1803581555117916160 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR033323690</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519232554.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s1996 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00019053-199600102-00007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR033323690</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00019053-199600102-00007-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.40</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Schöffski, Oliver</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1996</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary For many years, drug prices in Germany were the highest in Europe and the level of regulation of the pharmaceutical industry was lower than in other states. This situation has, however, changed radically in recent years. Pharmaceutical prices have been regulated, without the introduction of direct price controls, through a combination of pressures exerted by the authorities and the German sickness funds, which are responsible for reimbursement. The process of price restriction began in 1984 with the imposition of a negative pharmaceuticals list, which was further extended in 1989. A reference pricing system was also introduced in 1989, and a drug budget for office-based physicians in 1993. An overview of these measures is provided in the first section of this article. This is followed by a report of a study of the impact of Germany’s global pharmaceutical budgets for office-based general practitioners and internists.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adis International Limited</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Reference Price</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Sickness Fund</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">German Physician</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Parallel Import</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">PharmacoEconomics</subfield><subfield code="d">Berlin [u.a.] : Springer, 1992</subfield><subfield code="g">10(1996), Suppl 2 vom: Dez., Seite 37-47</subfield><subfield code="w">(DE-627)327645717</subfield><subfield code="w">(DE-600)2043876-X</subfield><subfield code="x">1179-2027</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:10</subfield><subfield code="g">year:1996</subfield><subfield code="g">number:Suppl 2</subfield><subfield code="g">month:12</subfield><subfield code="g">pages:37-47</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00019053-199600102-00007</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-ASE</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.40</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">10</subfield><subfield code="j">1996</subfield><subfield code="e">Suppl 2</subfield><subfield code="c">12</subfield><subfield code="h">37-47</subfield></datafield></record></collection>
|
| score |
7.3985004 |